Castle Biosciences (CSTL) Free Cash Flow (2018 - 2026)

Castle Biosciences has disclosed Free Cash Flow across 9 years of filings, most recently posting -$34.6 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$34.6 million, down 273.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.9 million (down 41.56% YoY), and the FY2025 annual result was $62.2 million, down 4.06% from the prior year.
• Free Cash Flow came in at -$34.6 million for Q1 2026 at Castle Biosciences, down from $53.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $53.7 million in Q4 2025 to a low of -$34.6 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$3.6 million (2022), against an average of $1.8 million.
• Across the five-year window, Free Cash Flow plunged 389.89% in 2022 and soared 977.21% in 2024, its largest moves.
• Castle Biosciences' Free Cash Flow stood at -$3.6 million in 2022, then surged by 516.62% to $14.8 million in 2023, then soared by 205.02% to $45.1 million in 2024, then grew by 18.9% to $53.7 million in 2025, then tumbled by 164.46% to -$34.6 million in 2026.
• The last three Free Cash Flow figures came in at -$34.6 million (Q1 2026), $53.7 million (Q4 2025), and $616000.0 (Q3 2025), per Business Quant data.